Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Zhaopei Liu *Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-5288-5037
Lingkai Zhang *NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0009-0001-0405-057X
Kaifeng Jin *NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0000-0001-9867-6516
Han Zeng *Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID 0000-0001-6486-2038
Xiaohe SuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0009-0006-4951-2236
Yawei DingDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-2879-3642
Jiaxing SunDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0009-0004-5409-3959
Yuzhen WuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0009-0003-6616-653X
Hailong LiuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0003-2488-1239
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-3332-5202
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0003-6751-9261
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0000-0003-3494-3114
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0003-2042-9317
Jiejie XuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0000-0001-7431-9063
Funding
Beijing Xisike Clinical Oncology Research Foundation (CSCO Foundation) Y-Gilead2024-PT-0098Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission 24CGA07China Postdoctoral Science Foundation (China Postdoctoral Foundation Project) 2024M760547China Postdoctoral Science Foundation (China Postdoctoral Foundation Project) BX20230091Chongqing Postdoctoral Program for Innovative Talents CQBX202426Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation YJYQ201802Key Project of Young Doctor Incubation Program of the Second Affiliated Hospital of Army Medical University 2024YQB024National Natural Science Foundation of China (NSFC) 82272786National Natural Science Foundation of China (NSFC) 82272930National Natural Science Foundation of China (NSFC) 82372793National Natural Science Foundation of China (NSFC) 82373276Natural Science Foundation of Shanghai Municipality () 22ZR1413400Natural Science Foundation of Shanghai Municipality () 23ZR1411700Natural Science Foundation of Shanghai Municipality () 23ZR1440300Natural Science Foundation of Shanghai Municipality () 24SF1901304Shanghai Anticancer Association EYAS PROJECT SACA-CY22B02Shanghai Anticancer Association EYAS PROJECT SACA-CY24C10Shanghai Anticancer Association EYAS PROJECT ZYJH202309Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 20224Y0232Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 202340127Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 202340195Shanghai Sailing Program 24YF2705400Shanghai Sailing Program 24YF2706000Youth Foundation of Zhongshan Hospital affiliated with Fudan University ZSZP202405
6 · The paper itself
Abstract
purposeARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain poorly understood. EXPERIMENTAL
designThe clinical relevance of ARID1A loss and CD8+ T-cell infiltration was evaluated in three cohorts [Zhongshan Hospital, Fudan University (ZSHS), n = 135; Fudan University Shanghai Cancer Center (FUSCC), n = 118; and IMvigor210, n = 274]. Immune microenvironment profiling was performed via IHC in the ZSHS cohort and transcriptomics in the IMvigor210 cohort. The Shanghai-sequencing cohort (n = 134) provided genomic characterization of ARID1A-loss patients.
resultsARID1A loss did not affect overall survival and CD8+ T-cell infiltration in both ZSHS and FUSCC cohorts. Only in ARID1A-loss urothelial carcinoma, high infiltration of CD8+ T cells yielded favorable outcomes (ZSHS cohort, log-rank P = 0.010; FUSCC cohort, log-rank P = 0.015). Moreover, ARID1Aloss CD8high patients displayed improved survival following adjuvant chemotherapy (log-rank P = 0.015) and PD-1/PD-L1 blockade (log-rank P = 0.020). In ARID1A-loss urothelial carcinoma, the enhanced antitumor function of CD8+ T cells might be affected by tertiary lymphoid structures. Furthermore, ARID1Aloss CD8high patients exhibited an antitumor immune contexture characterized by decreased immune-suppressive cells such as DC-SIGN+ tumor-associated macrophages, PDPN+ cells, and TGF-β+ cells, as well as lower expression of checkpoints such as B7-H3 and B7-H4.
conclusionsThe combination of ARID1A loss plus CD8+ T-cell infiltration indicated a favorable prognosis and responsiveness to both chemotherapy and immunotherapy. These findings provide valuable insights for developing novel therapeutic strategies and improving treatment stratification for urothelial carcinoma.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma. · full record | OpenQuestion